BayBridge Capital Group LLC Has $453,000 Stock Holdings in GSK plc (NYSE:GSK)

BayBridge Capital Group LLC increased its holdings in shares of GSK plc (NYSE:GSK) by 7.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,086 shares of the pharmaceutical company’s stock after buying an additional 807 shares during the quarter. BayBridge Capital Group LLC’s holdings in GSK were worth $453,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Eastern Bank acquired a new stake in GSK during the 3rd quarter worth about $26,000. Register Financial Advisors LLC purchased a new stake in shares of GSK in the first quarter worth approximately $31,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of GSK during the second quarter worth approximately $37,000. PrairieView Partners LLC purchased a new position in GSK during the second quarter valued at approximately $47,000. Finally, Triad Wealth Partners LLC acquired a new position in GSK in the 2nd quarter valued at approximately $49,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.00% of the company’s stock.

GSK Price Performance

NYSE GSK opened at $37.51 on Friday. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The stock’s 50-day moving average is $41.12 and its two-hundred day moving average is $41.14. The firm has a market cap of $77.74 billion, a P/E ratio of 13.59, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The company had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. On average, analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were issued a $0.3843 dividend. The ex-dividend date was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a yield of 4.10%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 55.80%.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of research reports. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group increased their price objective on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.